PepGen Inc. (PEPG)
Bid | 1.54 |
Market Cap | 52.63M |
Revenue (ttm) | n/a |
Net Income (ttm) | -89.98M |
EPS (ttm) | -2.85 |
PE Ratio (ttm) | -0.56 |
Forward PE | -0.63 |
Analyst | Buy |
Ask | 1.58 |
Volume | 250,037 |
Avg. Volume (20D) | 2,880,904 |
Open | 1.66 |
Previous Close | 1.62 |
Day's Range | 1.50 - 1.72 |
52-Week Range | 0.88 - 19.30 |
Beta | 1.42 |
About PEPG
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1...
Analyst Forecast
According to 3 analyst ratings, the average rating for PEPG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 645.34% from the latest price.
Stock Forecasts
17 hours ago · accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGNEW YORK CITY, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ:PEPG). Such investors are advised...

3 weeks ago · businesswire.com
PepGen to Present at the 24th Annual Needham Virtual Healthcare ConferenceBOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...

2 months ago · accessnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGNEW YORK CITY, NY / ACCESS Newswire / February 1, 2025 / SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG NEW YORK, February 1, 2025 (ACCESSWIRE) ...